1,721,101 research outputs found
Selective IgA deficiency: ruling out coeliac disease and selective antibody deficiency to polysaccharides
No full text
Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.
No full textEsperienze con le gammaglobuline per os nella terapia e prevenzione della diarrea infettiva.
No full text
A child with spastic tetraparesis who's not growing: A story in three parts
No full textRiprendiamo una vecchia rubrica e un
vecchio gioco quasi-interattivo di Medico
e Bambino: presentiamo un caso vero,
in cui c’è stato o non c’è stato un errore gestionale
da discutere, e cerchiamo di coinvolgere
il lettore, chiedendogli, lungo il
cammino, cosa avrebbe deciso di fare lui.
Attenzione: non cosa pensava, ma cosa
avrebbe fatto, anche se le scelte decisionali
non possono non avere dietro di sé un pensiero.
Ma le scelte sono le scelte e i pensieri
sono pensieri. Per questo il giudizio sulle
scelte viene dato a posteriori, sulla evoluzione
clinica successiva. Può essere che
uno abbia anche fatto delle scelte concettualmente
giustificate, ma sono i fatti a dare
torto o ragion
Upper gastrointestinal involvement in paediatric onset Crohn's disease: Prevalence and clinical implications
No full textBACKGROUND AND AIMS:
Our study evaluated the prevalence, the characteristics and implications of the upper gastrointestinal localisation (UGI+) in paediatric Crohn's Disease (CD) patients.
METHODS:
This prospective study evaluated 45 newly diagnosed CD patients at diagnosis and follow up with respect to CD localisation.
RESULTS:
All patients presented CD at the colon and/or ileum. In 24/45 patients (53.3%, 12 F and 12 M) an UGI+ involvement was also found. UGI+ patients had a younger age of onset (10.9 years versus 12.6 years; P<0.05). PCDAI at diagnosis was significantly higher in the UGI+ (41 vs. 25 P<0.01). UGI+ patients were overall more symptomatic. Pancolitis and extraintestinal manifestations were also more frequent (19/24 (80%) vs. 12/21 (57%) P<0.01). Growth was more impaired at diagnosis in UGI+ patients. By the end of the follow-up (mean 3 years, range 2 to 4) no significant difference was found in PCDAI (17 in UGI+ patients vs. 11 in UGI- P=NS), or the number of relapses. Weight and growth catch-up in UGI+ patients were comparable to UGI- ones. However, UGI+ patients required a more aggressive therapeutic approach.
CONCLUSION:
At least half of paediatric onset CD patients have an upper gastrointestinal localisation. UGI+ patients present an earlier onset and a more severe disease. The final outcome does not differ, but UGI+ patients require a more aggressive therapeutic approach
- …
